The novel β2-selective proteasome inhibitor LU-102 decreases phosphorylation of I kappa B and induces highly synergistic cytotoxicity in combination with ibrutinib in multiple myeloma cells

相似書籍

• The novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells
  由: Kraus, Marianne, et al.
  出版: (2015)
• Nelfinavir augments proteasome inhibition by bortezomib in myeloma cells and overcomes bortezomib and carfilzomib resistance
  由: Kraus, M, et al.
  出版: (2013)
• Proteasome inhibitor-adapted myeloma cells are largely independent from proteasome activity and show complex proteomic changes, in particular in redox and energy metabolism
  由: Soriano, G P, et al.
  出版: (2016)
• An inhibitor of proteasome β2 sites sensitizes myeloma cells to immunoproteasome inhibitors
  由: Downey-Kopyscinski, Sondra, et al.
  出版: (2018)
• The first-in-class alkylating HDAC inhibitor EDO-S101 is highly synergistic with proteasome inhibition against multiple myeloma through activation of multiple pathways
  由: Besse, L, et al.
  出版: (2017)